Use this internal resource to keep sourcing, documentation, and RFQ discussion on the same page.
AHPX+ pairs 1,000 ppm Acetyl Hexapeptide-8 with a patent-pending hydrolyzed chitosan carrier (CN120248173A).
AHPX+ pairs 1,000 ppm Acetyl Hexapeptide-8 with a patent-pending hydrolyzed chitosan carrier (CN120248173A).
AHPX+ (Acetyl Hexapeptide-8 Pro) Chitosan Carrier Complex
Carrier-enhanced 1,000 ppm (0.1%) Acetyl Hexapeptide-8 aqueous cosmetic delivery complex paired with Suzhou Xilin’s patent-pending modified chitosan carrier (CN120248173A). Demonstrated +82% (2h) and +219% (8h) ex-vivo skin permeation vs. unmodified hexapeptide and 28-day human split-face substantiation (GQI, n = 33).
Patent-pending modified chitosan carrier (CN120248173A)+219% 8h ex-vivo skin uptake (3.19× vs. free peptide)28-day GQI split-face human study (n = 33)Compliant existing INCI (no mutated sequence risk)
Review specifications, files, and next-step support before requesting samples.
- Confirm the peptide name, CAS, and core specifications
- Check typical applications and document availability
- Use one inquiry path for pricing, files, samples, or project discussion
Direct Answer
Ingredient identity for buyer review
Confirm naming, CAS, document scope, and inquiry intent before sample, MOQ, lead-time, or bulk quotation discussion.
- Market Name
- AHPX+ / Acetyl Hexapeptide-8 Pro (1,000 ppm Liquid Delivery Complex)
- INCI Name
- Water, Acetyl Hexapeptide-8, Hydrolyzed Chitosan, Hydroxyacetophenone, Pentylene Glycol (1,2-Pentanediol)
- Synonym
- Chitosan-Carried Acetyl Hexapeptide-8 Aqueous Delivery Complex
- CAS No.
- 616204-22-9 (Acetyl Hexapeptide-8) · Compounded Aqueous System
- Typical Formats
- 1 kg / 5 kg / 25 kg HDPE cosmetic drums; evaluation samples available for B2B labs
- Common Review Documents
- Batch COA, Quantitative % INCI Breakdown, TDS, 16-Section GHS SDS, GQI Study Summary
- Buyer Intent
- Prestige expression-line serums, eye creams (ISO 22716 eye-care scope), and clinical ODM lines
Quick Answer
AHPX+ (Acetyl Hexapeptide-8 Pro, CN120248173A): transdermal carrier & GQI clinical summary
B2B sourcing noteAHPX+ is Suzhou Xilin’s proprietary 1,000 ppm (0.1%) aqueous cosmetic delivery system pairing Acetyl Hexapeptide-8 with a patent-pending amphiphilic modified-chitosan carrier (CN120248173A, co-invented by Dr. Yiqiong Ji & Dr. Libo Du). It preserves standard INCI compliance while delivering +82.00% (2h) and +219.00% (8h, 3.19×) ex-vivo skin permeation, -32.0% acetylcholine release inhibition at 1/10th concentration (0.005 mg/mL), and GQI 28-day 33-subject split-face crow’s-feet reduction (-38.49% volume, -30.40% length).
Naming comparison table
| Name / term | How buyers should read it | RFQ action |
|---|---|---|
| Full INCI Declaration | Water, Acetyl Hexapeptide-8, Hydrolyzed Chitosan, Hydroxyacetophenone, Pentylene Glycol. | Zero novel-ingredient barrier—every component is an established cosmetic INCI entry. |
| Patent-Pending Carrier (CN120248173A) | Application CN202510660611.7 (Substantive Examination), Suzhou Xilin Technology Co., Ltd. | Self-assembling modified chitosan overcomes the >500 Da stratum corneum barrier. |
| Commercial Supply Formats | 1 kg / 5 kg / 25 kg liquid active drums, bulk compounded kg/L bases, or phased ODM. | Recommended formula dosage: 0.5%–5.0% w/w added at ≤45 °C (pH 4.8–7.0). |
B2B specification review table
| Review item | Buyer check |
|---|---|
| Ex-vivo permeation (mouse skin) | +82.00% fluorescence at 2 h (1.82×) and +219.00% at 8 h (3.19×) vs. unmodified Acetyl Hexapeptide-8. |
| In-vitro potency (1/10th dose) | -32.0% acetylcholine inhibition at 0.005 mg/mL vs. -18.3% for unmodified hexapeptide at 0.05 mg/mL; Type III collagen +794.1%. |
| GQI 28-day human trial (n = 33) | 1% AHPX+ cream split-face study: -25.32% (7d) / -38.49% (28d) crow’s-feet volume, -30.40% length, +17.46% R2 elasticity, -22.58% TEWL. |
| Manufacturing & export pack | Produced at Suzhou Xilin (ISO 22716:2007 Cert. 27825-2025GPOC00009R000) with COA, % INCI breakdown, TDS, and 16-section English GHS SDS. |
Use this internal resource to keep sourcing, documentation, and RFQ discussion on the same page.
Use this internal resource to keep sourcing, documentation, and RFQ discussion on the same page.
Specifications
Specifications
Review the core data firstCheck the technical points buyers usually confirm before pricing or sample discussion.
Market NameAHPX+ / Acetyl Hexapeptide-8 Pro (1,000 ppm Liquid Delivery Complex)
INCI NameWater, Acetyl Hexapeptide-8, Hydrolyzed Chitosan, Hydroxyacetophenone, Pentylene Glycol (1,2-Pentanediol)
SynonymChitosan-Carried Acetyl Hexapeptide-8 Aqueous Delivery Complex
CAS No.616204-22-9 (Acetyl Hexapeptide-8) · Compounded Aqueous System
AppearanceClear to slightly opalescent colorless to pale-yellow water-soluble liquid
Active Peptide Load1,000 ppm (0.10% w/w) Acetyl Hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2)
Carrier Patent StatusCN120248173A (CN202510660611.7, Patent Pending — Inventors: Yiqiong Ji & Libo Du)
Recommended Dosage0.5% – 5.0% w/w in finished formulas (= 5 – 50 ppm net active hexapeptide; 1.0% / 10 ppm tested in GQI split-face cream)
Processing Temperature & pHAdd during cool-down phase at ~45 °C (≤45 °C); recommended finished formula pH 4.5 – 7.5
Typical Formats1 kg / 5 kg / 25 kg HDPE cosmetic drums; evaluation samples available for B2B labs
Common Review DocumentsBatch COA, Quantitative % INCI Breakdown, TDS, 16-Section GHS SDS, GQI Study Summary
Buyer IntentPrestige expression-line serums, eye creams (ISO 22716 eye-care scope), and clinical ODM lines
Explore Dual-PhD carrier research, patent-pending modified-chitosan delivery, and 4 flexible cosmetic ODM tracks.
Inspect on-site booth photos, ISO 22716:2007 cosmetic GMP certificate, and buyer Q&A from Guangzhou.
Typical Applications
Typical Applications
- Expression-line & dynamic-wrinkle facial serums (benchmarking prestige neuro-peptide + PHA/niacinamide serums)
- Firming eye contour creams and gels (supported by Suzhou Xilin ISO 22716 eye-care production scope)
- Pro-Xylane + Pro-hexapeptide dual-pathway anti-aging emulsions
- Cooling post-procedure soothing & firming hydrogel masks
MOQ / Lead Time / Samples
Commercial follow-up usually starts here.
- Sample availability can be confirmed for qualified projects
- MOQ and lead time are shared during inquiry
- Pricing and file requests can be handled together
Why buyers trust WUMO
Real content, documented — not guesswork
In peptide sourcing, chromatographic purity and delivered quantity require separate evaluation. We keep purity and labeling basis distinct on available documentation, so buyers can review analytical parameters for their quoted batch before ordering.
Purity vs quantity distinction
Purity (%) and reported quantity are distinct analytical parameters. Review purity and reported quantity separately, and confirm the labeling and assay basis for the batch proposed for your order.
Batch-specific documents
Batch documentation reflects the specific lot produced. Ask which batch-specific documents are available for the quoted lot, including COA and supporting HPLC or MS records where applicable.
Documented before commitment
Ingredient identity (INCI / CAS), specification sheet, and SDS are available for technical review. Confirm documentation for the batch proposed for your order before purchase.
Technical & Analytical Video Briefs
AHPX+ (Acetyl Hexapeptide-8 Pro) Chitosan Carrier Complex — Video Walkthroughs & Study Benchmarks
Watch analytical verification, solubility & specification parameters, transdermal delivery data, and reference formulation study walkthroughs with full transcripts.
Carrier Delivery & Formulation Brief1:20
Delivery System Brief · Acetyl Hexapeptide-8 · 1:20
AHPX+ (Acetyl Hexapeptide-8 + Hydrolyzed Chitosan Carrier): Penetration & 28-Day Split-Face Study
Technical briefing on AHPX+ (patent-pending carrier CN120248173A), a 1,000 ppm cosmetic delivery system pairing Acetyl Hexapeptide-8 with a hydrolyzed chitosan carrier to enhance transdermal uptake. Reviews preclinical mouse-skin fluorescence penetration (+82% at 2 h, +219% at 8 h vs peptide alone) and a 28-day split-face study at Guangzhou Quality Supervision & Testing Institute on 33 adults using a 1% AHPX+ cream (-38.49% crow’s-feet volume, -30.4% length, +17.46% / ~17.6% R2 elasticity vs baseline).
Verification scope:Hydrolyzed chitosan peptide delivery concept (CN120248173A), preclinical penetration & GQI 28-day split-face data
Jump to timestamp:
Key Verifiable Points & Parameters
- Delivery Architecture: Pairs Acetyl Hexapeptide-8 with a patent-pending hydrolyzed chitosan carrier (CN120248173A) designed to improve hydrophilic peptide transport across the stratum corneum.
- Preclinical Fluorescence Penetration (Mouse Skin Model): Carrier formula showed +82% higher relative fluorescence at 2 hours and +219% (3.19×) higher at 8 hours compared with Acetyl Hexapeptide-8 alone.
- 28-Day Split-Face Study Design (GQI, n = 33): 33 adult volunteers comparing a cream containing 1% AHPX+ against a comparator cream from Day 0 to Day 28.
- Measured Day 28 Split-Face Outcomes: Crow’s-feet volume decreased by 38.49%, length decreased by 30.4%, and the Cutometer R2 gross elasticity parameter increased by 17.46% (~17.6% rounded in video) vs baseline on the 1% AHPX+ side.
Read Verbatim Transcript, Summary & Verification Scope
Summary:Technical briefing on AHPX+ (patent-pending carrier CN120248173A), a 1,000 ppm cosmetic delivery system pairing Acetyl Hexapeptide-8 with a hydrolyzed chitosan carrier to enhance transdermal uptake. Reviews preclinical mouse-skin fluorescence penetration (+82% at 2 h, +219% at 8 h vs peptide alone) and a 28-day split-face study at Guangzhou Quality Supervision & Testing Institute on 33 adults using a 1% AHPX+ cream (-38.49% crow’s-feet volume, -30.4% length, +17.46% / ~17.6% R2 elasticity vs baseline).
Verbatim Audio / Visual Transcript:Meet AHPX+, a cosmetic ingredient system built around Acetyl Hexapeptide-8. Computational screening helped guide peptide selection. The selected peptide is paired with a hydrolyzed chitosan carrier. In a mouse skin model, the carrier formula showed higher relative fluorescence than the peptide alone at 2 and 8 hours (+82% at 2 h and +219% at 8 h vs peptide alone; supplier-reported preclinical data). Laboratory assays also explored the peptide’s molecular interactions. The supplier then conducted a 28-day half-face study with 33 adults comparing a cream containing 1% AHPX+ with a comparator cream. At day 28, measured crow’s-feet length fell 30.4%, while the R2 elasticity parameter rose 17.6% from baseline on the AHPX+ side. Explore AHPX+ for skincare designed to improve the appearance of fine lines and firmness. For cosmetic formulation development.
Editorial & Verification Scope Note:Preclinical fluorescence penetration and 28-day split-face figures reflect data for the tested 1% AHPX+ carrier formulation (n = 33, Guangzhou Quality Supervision & Testing Institute). Confirm whether your inquiry requires neat Acetyl Hexapeptide-8 powder (CAS 616204-22-9) or the 1,000 ppm AHPX+ carrier complex when requesting specifications and samples.
Documents Available
Documents Available
Spec
AHPX+ Technical Data Sheet (TDS) & % INCI Compositional Breakdown
Request scope and availability through the B2B inquiry path.
Request this file through the inquiry path below.
COA
Batch Certificate of Analysis (COA — HPLC Peptide Assay & Microbial QC)
Batch-level quality summary for buyer-side file review.
Request this file through the inquiry path below.
Analytical File
28-Day Split-Face Instrumental Study Summary (GQI, n = 33)
Request scope and availability through the B2B inquiry path.
Request this analytical file through the inquiry path below.
Safety
16-Section English GHS Safety Data Sheet (SDS)
Safety document requested for internal purchasing and handling review.
Request this safety document through the inquiry path below.
Overview
Overview
AHPX+ (also referenced on B2B raw-material schedules as Acetyl Hexapeptide-8 Pro) is a drop-in aqueous cosmetic delivery system engineered by Dr. Yiqiong Ji and Dr. Libo Du at Suzhou Xilin Technology Co., Ltd. Rather than mutating the hexapeptide sequence—which would trigger new-cosmetic-ingredient registration barriers in the EU, UK, China, and Brazil—AHPX+ encapsulates standard 1,000 ppm (0.1%) Acetyl Hexapeptide-8 (CAS 616204-22-9) within a self-assembling amphiphilic modified-chitosan matrix (registered INCI: Hydrolyzed Chitosan, Chinese invention patent application CN120248173A ↗, patent pending).
Important Pricing & Specification Distinction: Unlike neat lyophilized Acetyl Hexapeptide-8 raw powder (which falls within China’s YY/T 10004—2026 solid-powder industry standard and is quoted per gram), AHPX+ is a ready-to-formulate 1,000 ppm liquid delivery complex quoted per kilogram for cold-process (≤45 °C) cosmetic compounding.
Details
Details
Why Hydrophilic Hexapeptides Need a Carrier System
Acetyl Hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, average MW 889.01 g/mol, monoisotopic mass 888.42 Da) carries multiple charged glutamyl and arginyl side chains. While highly water-soluble, its molecular mass exceeds the classic 500 Da stratum corneum diffusion threshold and its hydrophilicity limits partitioning across intercellular lipid lamellae. In conventional aqueous dilutions, most applied peptide remains on the skin surface unless high concentrations or barrier-disruptive enhancers are used.
Drawing on 15+ years of peer-reviewed chitosan nanoparticle and radical-chemistry research (see verified DOI bibliography), AHPX+ pairs Acetyl Hexapeptide-8 with low-molecular-weight modified chitosan (CN120248173A) via reversible electrostatic and hydrogen-bonding interactions—improving cutaneous residence and trans-corneal transport while preserving 100% mainstream global INCI compliance.
Verified Preclinical & Human Instrumental Data Summary
| Evaluation Tier | Protocol & Model | Measured Outcome |
|---|---|---|
| Ex-Vivo Skin Permeation | Fluorescence-labeled hexapeptide across excised mouse skin at 2 h and 8 h (AHPX+ carrier vs. unmodified peptide control) | +82.00% relative fluorescence intensity at 2 h (1.82×) and +219.00% at 8 h (3.19× uptake) |
| Neurotransmitter Release Assay | In-vitro acetylcholine (ACh) release inhibition comparing 0.005 mg/mL AHPX+ vs. 0.05 mg/mL standard hexapeptide |
-32.0% ACh release at 0.005 mg/mL (1/10th concentration), outperforming 10× higher dose of unmodified hexapeptide (-18.3%) |
| Dermal Matrix In-Vitro Expression | Fibroblast extracellular matrix markers at 0.01 mg/mL AHPX+ vs. untreated blank & market Pro-peptide comparator |
Type III Collagen +794.1% vs. blank (+182.3% vs. comparator); Type I Collagen +193.3%; Elastin +73.1% |
| 28-Day Split-Face Human Trial (GQI) | Guangzhou Quality Supervision & Testing Institute (广州质检院), n = 33 adults (ages 30–60), 1% AHPX+ cream twice daily for 28 days |
Crow’s-feet volume -25.32% (7d) / -38.49% (28d); length -30.40%; wrinkle area -24.71%; F4 firmness -22.25%; R2 elasticity +17.46%; TEWL -22.58%; hydration +31.69% |
Formulation & Co-Compatibility Guidelines
- Recommended Use Level:
0.5% – 5.0% w/win serums, eye creams, lotions, or hydrogel masks (1.0% w/wcorresponds to the human split-face test level). - Thermal & Addition Window: Incorporate during the cooling phase below
45 °Cunder gentle homogenization. - pH & Ionic Compatibility: Stable across
pH 4.5 – 7.5. When co-formulating with polyhydroxy acids (e.g.,5% Gluconolactone / PHA+5% Niacinamide) or anionic carbomers/xanthan gums, pre-buffer the acid phase topH ≥ 4.8before adding AHPX+ to prevent cationic-anionic polyelectrolyte flocculation. - Methionine Oxidation Protection: Because Acetyl Hexapeptide-8 contains a thioether Methionine residue (Met-3), avoid unquenched peroxides and pair with mild chelators/antioxidants (such as Hydroxyacetophenone already integrated in the AHPX+ vehicle).
Related Peptides
Compare related ingredients without restarting the review.
Peptide Raw Materials
Acetyl Hexapeptide-8
Cosmetic peptide commonly reviewed for expression-line care and skin-smoothing formulation projects in serums, creams, masks, and related facial care formats.
COA/SDS AvailableSample SupportBulk Inquiry
Peptide Raw Materials
Copper Tripeptide-1 (GHK-Cu)
Cosmetic peptide commonly reviewed for premium skin-care, skin-comfort, and multi-functional facial care formulation projects in serums, creams, masks, and related product formats.
COA/SDS AvailableSample SupportBulk Inquiry
Finished Formulation Concepts
AHPX+ & Pro-Xylane Firming Eye & Face Cream Concept
Dual-pathway AHPX+ chitosan hexapeptide + Pro-Xylane lamellar cream concept for eye & facial ODM programs.
FAQ
Frequently Asked Questions
Is CN120248173A a granted patent or patent-pending application?
CN120248173A (Application No. CN202510660611.7, filed May 21, 2025, published July 4, 2025 by Suzhou Xilin Technology Co., Ltd., inventors Yiqiong Ji & Libo Du) is a Chinese invention patent application currently in substantive examination (patent pending).
Can AHPX+ be co-formulated with polyhydroxy acids (PHA) and niacinamide?
Yes. When buffered in a controlled pH 4.8–5.5 window using lactobionic acid or gluconolactone (PHA) and added during cool-down (≤45 °C), AHPX+ supports multi-pathway smoothing and firming serums without strong-acid hydrolysis.
Is AHPX+ a powder quoted per gram or a liquid complex quoted per kilogram?
AHPX+ is a 1,000 ppm (0.1%) aqueous carrier-enhanced liquid complex quoted per kilogram (available in evaluation samples and 1 kg / 5 kg / 25 kg cosmetic drums). If your lab prefers to compound from 100% solid lyophilized peptide powder, review our neat Acetyl Hexapeptide-8 raw powder instead.
Does AHPX+ require new cosmetic ingredient registration in the EU, US, or China?
No. Every component in AHPX+ uses established cosmetic INCI nomenclature ( Water, Acetyl Hexapeptide-8, Hydrolyzed Chitosan, Hydroxyacetophenone, Pentylene Glycol ) listed in EU CosIng, US PCPC ICID, and China IECIC (2021). Quantitative % w/w compositional bands and impurity declarations are provided under NDA to support EU/UK CPSR & PIF compilation.
What is the patent status of the modified chitosan carrier?
The modified chitosan permeation-enhancer system is covered by Chinese Invention Patent Application CN120248173A (Application No. CN202510660611.7, filed May 21, 2025, published July 4, 2025, currently under substantive examination / patent pending), filed by Suzhou Xilin Technology Co., Ltd. and co-invented by Dr. Yiqiong Ji and Dr. Libo Du.
Cosmetic Pro-Peptide Delivery & Flexible ISO 22716 ODM
Developing a mid-to-high-end skincare or scalp SKU with AHPX+ (Acetyl Hexapeptide-8 Pro) Chitosan Carrier Complex?
Compare neat raw actives, AHPX+ modified-chitosan delivery complex
(CN120248173A, +219% 8h skin permeation), bulk compounded
kg / liter semi-finished bases, and phased custom-packaged ODM at
Suzhou Xilin Technology Co., Ltd. (ISO 22716:2007 Cert. 27825-2025GPOC00009R000,
covering liquid & eye-care/cream scope): explore our Pro-Peptide Science & ODM Hub or Finished Skincare OEM / ODM Service.
Request AHPX+ (Acetyl Hexapeptide-8 Pro) Chitosan Carrier Complex Batch COA, Sample, or Bulk / ODM Pricing
Share your target format (raw active by g/kg, bulk semi-finished base by kg/liter, or custom-packaged ODM), target active %, and destination market (EU PIF/CPSR, UK SCPN, US MoCRA, ANVISA).